When should you suspect community-acquired MRSA? How should you treat it?

Evidence-based answer
There are no clinical or epidemiologic features that will help you to clearly distinguish community-acquired methicillin-resistant Staphylococcus aureus infections (CA-MRSA) from methicillin-sensitive (CA-MSSA) infections (strength of recommendation [SOR]: B, prospective cohort studies).

Incision and drainage is the primary therapy for purulent skin and soft tissue infections (SOR: B, randomized, controlled clinical trials [RCTs]). There are inadequate data evaluating the role of oral antibiotics for MRSA (SOR: B, single RCT).

Evidence summary
Two prospective cohort studies have looked at the usefulness of clinical characteristics to help differentiate MRSA from MSSA infections. The studies—a 2002 observational study of 144 children and a 2007 study of 180 consecutively enrolled adults—found no clear distinguishing features for MRSA. They did note some commonly associated risk factors, however (TABLE). Abscess formation was the most common presentation of CA-MRSA, followed by purulent cellulitis. The prevalence and incidence of nonpurulent CA-MRSA is not well defined.

Best treatment bet: Incision and drainage
Incision and drainage remains the mainstay of abscess treatment. A 2007 RCT of 166 indigent, inner-city patients with confirmed MRSA investigated combining incision and drainage with 7 days of therapy using either cephalexin or placebo. The primary outcome was clinical cure or failure 7 days after incision and drainage. The trial found no advantage to adding antibiotics; MRSA would likely be resistant to cephalexin in any case.

A 2006 summary from Clinical Evidence found no RCT support for any outpatient antibiotic. No evidence exists that intranasal mupirocin or antiseptic body washes reduce the recurrence rate. We found no studies evaluating the optimal treatment of purulent skin and soft tissue infections without abscesses.

Avoid fluoroquinolones
MRSA isolates demonstrate a high resistance to fluoroquinolones, so this class of drugs isn’t recommended.

Recommendations
The Centers for Disease Control and Prevention (CDC) recommends the following treatment for CA-MRSA:
- drain all abscesses; incision and drainage alone suffices for immunocompetent patients
- for other patients, consider adjunct
treatment with clindamycin, trimethoprim and sulfamethoxazole, tetracyclines, or linezolid. The CDC also recommends consulting an infectious disease specialist before using linezolid and avoiding fluoroquinolone and macrolide antibiotics because resistance develops rapidly.8 Rifampin can be used in combination with other standard treatments.8

The CDC doesn’t recommend treating nonpurulent skin infections with CA-MRSA-specific antibiotics. These infections are generally caused by Staphylococcus pyogenes and remain sensitive to β-lactam antibiotics. When the community prevalence of CA-MRSA is low, a β-lactam antibiotic can be used with close follow-up.8

The Infectious Diseases Society of America recommends incision and drainage for abscesses and treatment with CA-MRSA-specific antibiotics for purulent skin infections.9

References